278 related articles for article (PubMed ID: 38426102)
1. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management.
Lin MX; Zang D; Liu CG; Han X; Chen J
Front Immunol; 2024; 15():1266850. PubMed ID: 38426102
[TBL] [Abstract][Full Text] [Related]
2. Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.
Li X; Yang F; Liu B; Ye L; Du J; Fan X; Yu Y; Li M; Bu L; Zhang Z; Xie L; Li W; Qi J
J Immunother; 2024 Jul-Aug 01; 47(6):220-226. PubMed ID: 38618919
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
Zhou P; Zhao X; Wang G
Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
[TBL] [Abstract][Full Text] [Related]
4. Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC.
Mao Z; Pang G; Huang X; Chen X; Wu J; Xu X; Teng Z; Tan Y; Wang P
BMC Pulm Med; 2024 May; 24(1):253. PubMed ID: 38783253
[TBL] [Abstract][Full Text] [Related]
5. Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).
Hu X; Ren J; Xue Q; Luan R; Ding D; Tan J; Su X; Yang J
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37681488
[TBL] [Abstract][Full Text] [Related]
6. Clinical Characteristics, Management and Prognostic Factors of Immune Checkpoint Inhibitor-Associated Pneumonia in Chinese Cancer Patients.
Li J; Chen S; Yan T; Zeng M
J Coll Physicians Surg Pak; 2024 Mar; 34(3):302-307. PubMed ID: 38462865
[TBL] [Abstract][Full Text] [Related]
7. Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation.
Zhu S; Fu Y; Zhu B; Zhang B; Wang J
Front Oncol; 2020; 10():1785. PubMed ID: 33042827
[TBL] [Abstract][Full Text] [Related]
8. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors.
Shibata Y; Murakami S; Kato T
Expert Opin Drug Saf; 2021 May; 20(5):537-547. PubMed ID: 33650443
[No Abstract] [Full Text] [Related]
9. [Establish a whole-process comprehensive surveillance management mode for immune checkpoint inhibitor pneumonitis].
Xu Y; Pan RL; Huang H; Wang MZ
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Aug; 57(8):1176-1180. PubMed ID: 37574309
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
[TBL] [Abstract][Full Text] [Related]
11. Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis.
Yu X; Wu J; Su C
Curr Opin Oncol; 2023 Jan; 35(1):31-36. PubMed ID: 36322006
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond.
Reuss JE; Suresh K; Naidoo J
Curr Oncol Rep; 2020 May; 22(6):56. PubMed ID: 32415399
[TBL] [Abstract][Full Text] [Related]
13. Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer.
Tao H; Li F; Wu D; Ji S; Liu Q; Wang L; Liu B; Facchinetti F; Leong TL; Passiglia F; Hu Y
Transl Lung Cancer Res; 2022 Mar; 11(3):381-392. PubMed ID: 35399572
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary toxicities of immune check point inhibitors in the management of cancer: mini review.
Jayakrishnan B; Al-Moundhri M; Burney I; Al-Hashami Z; Al-Bimani K
Adv Respir Med; 2022; 90(3):219-229. PubMed ID: 35731114
[TBL] [Abstract][Full Text] [Related]
15. Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies.
Guo X; Chen S; Wang X; Liu X
Front Immunol; 2023; 14():1138483. PubMed ID: 37081866
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study.
Lin X; Deng H; Chu T; Chen L; Yang Y; Qiu G; Xie X; Qin Y; Liu M; Xie Z; Ouyang M; Li S; Song Y; Petrella F; Jakopovic M; Tsoukalas N; Solli P; Goto T; Saito Y; Zhou C
Transl Lung Cancer Res; 2022 Nov; 11(11):2289-2305. PubMed ID: 36519018
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.
Chao Y; Zhou J; Hsu S; Ding N; Li J; Zhang Y; Xu X; Tang X; Wei T; Zhu Z; Chu Q; Neal JW; Wu JT; Song Y; Hu J
Transl Lung Cancer Res; 2022 Feb; 11(2):295-306. PubMed ID: 35280322
[TBL] [Abstract][Full Text] [Related]
18. Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer.
Lin X; Deng H; Yang Y; Wu J; Qiu G; Li S; Xie X; Liu M; Xie Z; Qin Y; Song Y; Zhou C
Front Oncol; 2021; 11():698832. PubMed ID: 34327140
[TBL] [Abstract][Full Text] [Related]
19. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.
Yin J; Wu Y; Yang X; Gan L; Xue J
Front Immunol; 2022; 13():830631. PubMed ID: 35464480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
